114 related articles for article (PubMed ID: 36264776)
1. Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
Chen G; Zhu YJ; Chen J; Miao F; Wu N; Song Y; Mao BB; Wang SZ; Xu F; Chen ZM
Neoplasma; 2022 Dec; 69(6):1314-1321. PubMed ID: 36264776
[TBL] [Abstract][Full Text] [Related]
2. The effects of altered DNA damage repair genes on mutational processes and immune cell infiltration in esophageal squamous cell carcinoma.
Yuan H; Qing T; Zhu S; Yang X; Wu W; Xu K; Chen H; Jiang Y; Zhu C; Yuan Z; Zhang T; Jin L; Suo C; Lu M; Chen X; Ye W
Cancer Med; 2023 Apr; 12(8):10077-10090. PubMed ID: 36708047
[TBL] [Abstract][Full Text] [Related]
3. Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers.
Cerniglia M; Xiu J; Grothey A; Pishvaian MJ; Baca Y; Hwang JJ; Marshall JL; VanderWalde AM; Shields AF; Lenz HJ; Korn WM; Salem M; Philip PA; Goldberg RM; Zeng J; Kim SS
Mol Cancer Ther; 2022 Jan; 21(1):227-236. PubMed ID: 34725190
[TBL] [Abstract][Full Text] [Related]
4. Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma.
Guo JC; Lin CC; Hsu CL; Huang TC; Kuo HY; Lin CY; Lien MY; Cheng AL; Hsu CH
Esophagus; 2022 Oct; 19(4):693-701. PubMed ID: 35816242
[TBL] [Abstract][Full Text] [Related]
5. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
6. Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature.
Zhang P; Wen B; Gong J; Liu Z; Zhang M; Zhou G; Zhang L; Zhang Z
Environ Toxicol; 2024 May; 39(5):2803-2816. PubMed ID: 38287713
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing.
Wang HY; Deng L; Li YQ; Zhang X; Long YK; Zhang X; Feng YF; He Y; Tang T; Yang XH; Wang F
Cancer Res Treat; 2021 Oct; 53(4):973-982. PubMed ID: 33677848
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
Sasaki Y; Tamura M; Koyama R; Nakagaki T; Adachi Y; Tokino T
World J Gastroenterol; 2016 Feb; 22(7):2284-93. PubMed ID: 26900290
[TBL] [Abstract][Full Text] [Related]
11. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
[TBL] [Abstract][Full Text] [Related]
12. DNA damage repair profiling of esophageal squamous cell carcinoma uncovers clinically relevant molecular subtypes with distinct prognoses and therapeutic vulnerabilities.
Zhao N; Zhang Z; Wang Q; Li L; Wei Z; Chen H; Zhou M; Liu Z; Su J
EBioMedicine; 2023 Oct; 96():104801. PubMed ID: 37725855
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
15. Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.
Tian W; Shan B; Zhang Y; Ren Y; Liang S; Zhao J; Zhao Z; Wang G; Zhao X; Peng D; Bi R; Cai S; Bai Y; Wang H
Cancer Med; 2020 Mar; 9(6):2190-2200. PubMed ID: 31991061
[TBL] [Abstract][Full Text] [Related]
16. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
17. MYH9 promotes cell metastasis
Yang B; Liu H; Bi Y; Cheng C; Li G; Kong P; Zhang L; Shi R; Zhang Y; Zhang R; Cheng X
Int J Med Sci; 2020; 17(13):2013-2023. PubMed ID: 32788880
[TBL] [Abstract][Full Text] [Related]
18. [High throughput-targeted sequencing panel for exploring radiosensitivity associated genes in esophageal squamous cell carcinoma].
Qiao Y; Hu CX; Song DA; Li SQ; Zhou LH; Jiang XD
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):584-588. PubMed ID: 28835080
[No Abstract] [Full Text] [Related]
19. Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma.
Ohashi S; Kikuchi O; Nakai Y; Ida T; Saito T; Kondo Y; Yamamoto Y; Mitani Y; Nguyen Vu TH; Fukuyama K; Tsukihara H; Suzuki N; Muto M
Mol Cancer Ther; 2020 Jun; 19(6):1363-1372. PubMed ID: 32371587
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
